公开(公告)号：US20180237422A1

公开(公告)日：2018-08-23

申请号：US15554614

申请日：2016-03-11

Applicant: Merck Sharp & Dohme Corp.

Inventor： Dong-Ming Shen ,  Christopher J. Sinz ,  Alejandro Crespo ,  Johnathan E. Wilson ,  Troy McCraken ,  Shimin XU ,  Haitang Li

IPC: C07D403/04 ,  C07D471/04 ,  C07D487/04 ,  C07D498/04

CPC classification number: C07D403/04 ,  A61K31/4192 ,  A61K31/4196 ,  A61K31/506 ,  A61P25/00 ,  C07D471/04 ,  C07D487/04 ,  C07D498/04

Abstract: The present invention is directed to pyrimidine carboxamide compounds of formula I which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 2 (PDE2). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis, Parkinson's disease, Parkinson's disease dementia (PDD), or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.

公开(公告)号：US20180169072A1

公开(公告)日：2018-06-21

申请号：US15579878

申请日：2016-06-27

Applicant: Gregori J. MORRIELLO ,  Lehua CHANG ,  Ashley FORSTER ,  Yili CHEN ,  Michael P. DWYER ,  Zack Zhiqiang GUO ,  Ming WANG ,  Shimin XU ,  Yingjian BO ,  Jianmin FU ,  MERCK SHARP & DOHME CORP.

Inventor： Gregori J. MORRIELLO ,  Lehua CHANG ,  Ashley FORSTER ,  Yili CHEN ,  Michael P. DWYER ,  Zack Zhiqiang GUO ,  Ming WANG ,  Shimin XU ,  Yingjian BO ,  Jianmin FU

IPC: A61K31/4196 ,  A61K31/52 ,  A61P25/06 ,  A61P25/16 ,  A61P25/18 ,  A61P25/22 ,  A61P25/28

CPC classification number: A61K31/4196 ,  A61K31/52 ,  A61P25/06 ,  A61P25/16 ,  A61P25/18 ,  A61P25/22 ,  A61P25/28 ,  C07D471/04 ,  C07D487/04

Abstract: The present invention is directed to substituted triazolo bicyclic compounds of formula I which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 2 (PDE2). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis, Parkinson's disease, Parkinson's disease dementia (PDD), or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.